

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**21-623**

**MICROBIOLOGY REVIEW**

# **Product Quality Microbiology Review**

## **Review for HFD-170**

**17 DECEMBER 2003**

**NDA: 21-623**

**Drug Product Name**

**Proprietary: S-Caine Patch**

**Non-proprietary: lidocaine 70 mg/tetracaine 70 mg**

**Drug Product Priority Classification: S**

**Review Number: 1**

**Subject of this Review**

**Submission Date: 31 March 2003**

**Receipt Date: 4 April 2003**

**Consult Date: 2 October 2003**

**Date Assigned for Review: 20 October 2003**

**Submission History (for amendments only)**

**Date(s) of Previous Submission(s): N/A**

**Date(s) of Previous Micro Review(s): N/A**

**Applicant/Sponsor**

**Name: ZARS Inc.**

**Address: 350 West 800 North, Suite 320, Salt Lake City, Utah 84103**

**Representative: T. Andrew Crockett**

**Telephone:**

**Name of Reviewer: Bryan S. Riley, Ph.D.**

**Conclusion: Recommended for Approval**

## Product Quality Microbiology Data Sheet

- A.
1. **TYPE OF SUPPLEMENT:** N/A
  2. **SUPPLEMENT PROVIDES FOR:** N/A
  3. **MANUFACTURING SITE:** Tapemark Company  
1685 Marthaler Lane  
West St. Paul, MN 55118
  4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** Topical patch, 70 mg lidocaine and 70 mg tetracaine
  5. **METHOD(S) OF STERILIZATION:** N/A
  6. **PHARMACOLOGICAL CATEGORY:** Anesthetic
- B. **SUPPORTING/RELATED DOCUMENTS:** N/A
- C. **REMARKS:** none

filename: 21623.doc

---

**Executive Summary****I. Recommendations**

- A. Recommendation on Approvability** – This submission is recommended for approval on the basis of product quality microbiology.
- B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable** – N/A

**II. Summary of Microbiology Assessments**

- A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology** – The drug product is a non-sterile transdermal patch with a microbial limits release specification.
- B. Brief Description of Microbiology Deficiencies** – N/A
- C. Assessment of Risk Due to Microbiology Deficiencies** – The drug product has appropriate microbial limits specifications and presents minimal risk from the standpoint of product quality microbiology.

**III. Administrative**

- A. Reviewer's Signature** \_\_\_\_\_
- B. Endorsement Block**  
Bryan S. Riley, Ph.D. (Microbiology Reviewer)  
Peter H. Cooney, Ph.D. (Microbiology Supervisor)
- C. CC Block**  
N/A

1   Page(s) Withheld

  ✓   Trade Secret / Confidential

       Draft Labeling

       Deliberative Process

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Bryan Riley  
1/23/04 08:25:19 AM  
MICROBIOLOGIST

Peter Cooney  
1/23/04 09:21:46 AM  
MICROBIOLOGIST